173 related articles for article (PubMed ID: 25532482)
1. Thymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis.
Li C; Bo L; Liu Q; Jin F
Int J Infect Dis; 2015 Apr; 33():90-6. PubMed ID: 25532482
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials.
Liu F; Wang HM; Wang T; Zhang YM; Zhu X
BMC Infect Dis; 2016 Sep; 16():488. PubMed ID: 27633969
[TBL] [Abstract][Full Text] [Related]
3. Ulinastatin- and thymosin α1-based immunomodulatory strategy for sepsis: A meta-analysis.
Han D; Shang W; Wang G; Sun L; Zhang Y; Wen H; Xu L
Int Immunopharmacol; 2015 Dec; 29(2):377-382. PubMed ID: 26522590
[TBL] [Abstract][Full Text] [Related]
4. Ulinastatin and/or thymosin α1 for severe sepsis: A systematic review and meta-analysis.
Feng Z; Shi Q; Fan Y; Wang Q; Yin W
J Trauma Acute Care Surg; 2016 Feb; 80(2):335-40. PubMed ID: 26517783
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial.
Wu J; Zhou L; Liu J; Ma G; Kou Q; He Z; Chen J; Ou-Yang B; Chen M; Li Y; Wu X; Gu B; Chen L; Zou Z; Qiang X; Chen Y; Lin A; Zhang G; Guan X
Crit Care; 2013 Jan; 17(1):R8. PubMed ID: 23327199
[TBL] [Abstract][Full Text] [Related]
6. Effect of ulinastatin combined with thymosin alpha1 on sepsis: A systematic review and meta-analysis of Chinese and Indian patients.
Liu D; Yu Z; Yin J; Chen Y; Zhang H; Xin F; Fu H; Wan B
J Crit Care; 2017 Jun; 39():259-266. PubMed ID: 28069319
[TBL] [Abstract][Full Text] [Related]
7. The Efficacy and Immunomodulatory Effects of Ulinastatin and Thymosin α1 for Sepsis: A Systematic Review and Meta-Analysis.
Wang FY; Fang B; Qiang XH; Yu TO; Zhong JR; Cao J; Zhou LX
Biomed Res Int; 2016; 2016():9508493. PubMed ID: 27340674
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of efficacy of thymosin alpha1 in the treatment of sepsis: a systematic review].
Yu Y; Tian JH; Yang KH; Zhang P
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2009 Jan; 21(1):21-4. PubMed ID: 19141185
[TBL] [Abstract][Full Text] [Related]
9. Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond.
Danielli R; Fonsatti E; Calabrò L; Di Giacomo AM; Maio M
Ann N Y Acad Sci; 2012 Oct; 1270():8-12. PubMed ID: 23050811
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with thymosin alpha1 and dexamethasone helps mice survive sepsis.
Xiang XS; Li N; Zhao YZ; Li QR; Li JS
Inflammation; 2014 Apr; 37(2):402-16. PubMed ID: 24122349
[TBL] [Abstract][Full Text] [Related]
11. Thymosin alpha1- and ulinastatin-based immunomodulatory strategy for sepsis arising from intra-abdominal infection due to carbapenem-resistant bacteria.
Zhang Y; Chen H; Li YM; Zheng SS; Chen YG; Li LJ; Zhou L; Xie HY; Praseedom RK
J Infect Dis; 2008 Sep; 198(5):723-30. PubMed ID: 18613793
[TBL] [Abstract][Full Text] [Related]
12. Treatment of patients with severe sepsis using ulinastatin and thymosin alpha1: a prospective, randomized, controlled pilot study.
Chen H; He MY; Li YM
Chin Med J (Engl); 2009 Apr; 122(8):883-8. PubMed ID: 19493408
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulatory and enhanced antitumor activity of a modified thymosin α1 in melanoma and lung cancer.
Wang F; Li B; Fu P; Li Q; Zheng H; Lao X
Int J Pharm; 2018 Aug; 547(1-2):611-620. PubMed ID: 29933059
[TBL] [Abstract][Full Text] [Related]
14. A new immunomodulatory therapy for severe sepsis: Ulinastatin Plus Thymosin {alpha} 1.
Li Yumin ; Chen Hao ; Li Xun ; Zhou Wence ; He Minyan ; Chiriva-Internati M; Wachtel MS; Frezza EE
J Intensive Care Med; 2009; 24(1):47-53. PubMed ID: 19033321
[TBL] [Abstract][Full Text] [Related]
15. Effect of ulinastatin combined with thymosin alpha1 on sepsis: A systematic review and meta-analysis of Chinese and Indian patients.
Liu D; Yu Z; Yin J; Chen Y; Zhang H; Fan X; Fu H; Wan B
J Crit Care; 2017 Jun; 39():285-287. PubMed ID: 28283220
[TBL] [Abstract][Full Text] [Related]
16. Thymosin alpha 1 treatment for patients with sepsis.
Pei F; Guan X; Wu J
Expert Opin Biol Ther; 2018 Jul; 18(sup1):71-76. PubMed ID: 30063866
[TBL] [Abstract][Full Text] [Related]
17. The in vivo immunomodulatory and synergistic anti-tumor activity of thymosin α1-thymopentin fusion peptide and its binding to TLR2.
Li J; Cheng Y; Zhang X; Zheng L; Han Z; Li P; Xiao Y; Zhang Q; Wang F
Cancer Lett; 2013 Sep; 337(2):237-47. PubMed ID: 23684552
[TBL] [Abstract][Full Text] [Related]
18. Historical review of thymosin α 1 in infectious diseases.
Camerini R; Garaci E
Expert Opin Biol Ther; 2015; 15 Suppl 1():S117-27. PubMed ID: 26098768
[TBL] [Abstract][Full Text] [Related]
19. Historical review on thymosin α1 in oncology: preclinical and clinical experiences.
Garaci E; Pica F; Matteucci C; Gaziano R; D'Agostini C; Miele MT; Camerini R; Palamara AT; Favalli C; Mastino A; Serafino A; Sinibaldi Vallebona P
Expert Opin Biol Ther; 2015; 15 Suppl 1():S31-9. PubMed ID: 26096345
[TBL] [Abstract][Full Text] [Related]
20. Effect of a C-end rule modification on antitumor activity of thymosin α1.
Wang F; Xu C; Peng R; Li B; Shen X; Zheng H; Lao X
Biochimie; 2018 Nov; 154():99-106. PubMed ID: 30096371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
